Table 3.
Complication of Systemic Treatment
| Total | BMI (kg/m2) |
P-value | |||
|---|---|---|---|---|---|
| (N = 352) | < 25 |
≥ 25 |
|||
| N=185 | N=167 | ||||
| Complication | No | 187 (53.1) | 89 (48.1) | 98 (58.7) | 0.047* |
| Chemotherapy | Yes | 165 (46.9) | 96 (51.9) | 69 (41.3) | |
| Neutropenia | Grade 2 | 5 (1.4) | 2 (1.1) | 3 (1.8) | < 0.001* |
| Grade 3 | 5 (1.4) | 3 (1.6) | 2 (1.2) | ||
| Grade 4 | 123 (34.9) | 81 (43.8) | 42 (25.1) | ||
| Febrile neutropenia | No | 319 (90.6) | 162 (87.6) | 157 (94) | 0.038* |
| Yes | 33 (9.4) | 23 (12.4) | 10 (6) | ||
| Cardiomyopathy | No | 349 (99.1) | 184 (99.5) | 165 (98.8) | 0.503 |
| Yes | 3 (0.9) | 1 (0.5) | 2 (1.2) | ||
| Dose reduction | No | 190 (54) | 91 (49.2) | 99 (59.3) | 0.058 |
| Yes | 162 (46) | 94 (50.8) | 68 (40.7) | ||
| 1st Cycle | 8 | 0 | 8 | ||
| Other cycle | 154 | 94 | 60 | ||
| Complication | No | 283 (92.8) | 148 (91.9) | 135 (93.8) | 0.539 |
| Hormonal treatment | |||||
| Yes | 22 (7.2) | 13 (8.1) | 9 (6.2) | ||
| VTE | 2 | 2 | 0 | ||
| Hepatitis | 8 | 4 | 4 | ||
| Osteoporosis | 11 | 7 | 4 | ||
| Endometrial cancer | 2 | 1 | 1 | ||
VTE, Venous thromboembolism; *p-value < 0.05 statistical significance